<DOC>
	<DOCNO>NCT02603172</DOCNO>
	<brief_summary>GSK3039294 develop order offer orally available alternative parenteral CPHPC ( GSK2315698 [ metabolite GSK3039294 ] ) plasma serum amyloid P component ( SAP ) depletion prior use anti SAP monoclonal antibody ( mAb ) treatment systemic amyloidosis . This phase 1 study intend study safety , tolerability pharmacokinetic ( PK ) profile GSK3039294 humans . This study consist three part . Part A evaluate safety tolerability single dos GSK3039294 healthy subject , Part B evaluate safety tolerability repeat dose GSK3039294 healthy subject , Part C evaluate safety tolerability repeat dose GSK3039294 subject systemic amyloidosis . Part A single dose , open label , dose escalation study . Two cohort subject enrol provide data 6 subject per cohort 4 different dos ( 2 dose level per cohort ) GSK3039294 test . For Cohorts 1 2 , subject may take part two dosing period . Part B repeat dose , open label , dose escalation study . Sufficient number subject enrol Cohort 3a ensure 6 completers ( Cohort 3b conduct require ) GSK3039294 administer repeatedly total 21 day . Each subject take part single study period . In Part C single dose level GSK3039294 test 21 day repeat dose , 12 subject systemic amyloidosis . Each subject take part single study period . The total duration Part A approximately 8 week , Part B approximately 8-9 week , Part C approximately 13 week .</brief_summary>
	<brief_title>A Safety Study GSK3039294 Healthy Volunteers Patients With Systemic Amyloidosis</brief_title>
	<detailed_description />
	<mesh_term>Amyloidosis</mesh_term>
	<criteria>Age : 18 70 year age inclusive time signing informed consent . Nonsmokers Smokers . Smokers ( &lt; 5 /day ) permit must willing abstain duration residential study session / dose period ( whichever longer ) . Body weight &gt; 50 kilogram ( kg ) body mass index ( BMI ) within range 18.532 kg/square meter ( m^2 ) ( inclusive ) exclude effect peripheral oedema . Male female Female subject eligible participate nonchildbearing potential define premenopausal female document tubal ligation hysterectomy bilateral oophorectomy ; postmenopausal define 12 month spontaneous amenorrhea ( questionable case blood sample simultaneous follicle stimulate hormone ( FSH ) &gt; 40 milliinternational unit ( MIU ) /milliliter ( mL ) estradiol &lt; 40 picograms ( pg ) /mL ( 147 picomoles [ pmol ] /liter [ L ] ) confirmatory Male subject female partner child bear potential must comply one follow contraception requirement time first dose study medication completion followup visit : ( . ) Vasectomy documentation azoospermia ; ( b . ) Male condom plus partner use one follow contraceptive option : Contraceptive subdermal implant meet effectiveness criterion &lt; 1 % rate failure per year , state product label , Intrauterine device intrauterine system meet standard operate procedure ( SOP ) effectiveness criterion include &lt; 1 % rate failure per year , state product label , Oral Contraceptive either combine progestogen alone , Injectable progestogen , Contraceptive vaginal ring , Percutaneous contraceptive patch , Occlusive cap ( female diaphragm cervical/vault cap ) vaginal spermicide ( foam , gel , cream suppository ) . These allow method contraception effective use consistently , correctly accordance product label . The investigator responsible ensure subject understand properly use method contraception . Capable give sign informed consent include compliance requirement restriction list consent form protocol . Additional Inclusion Criteria Healthy Volunteers : Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . Additional Inclusion Criteria Healthy Volunteers : A subject clinical abnormality laboratory parameter ( ) is/are specifically list inclusion exclusion criterion , outside reference range population study may include investigator consultation Medical Monitor require agree document find unlikely introduce additional risk factor interfere study procedure . Additional Inclusion Criteria Healthy Volunteers : aspartate aminotransferase ( AST ) , alanine transaminase ( ALT ) , alkaline phosphatase bilirubin &lt; =1.5 upper limit normal ( ULN ) ( isolated bilirubin &gt; 1.5 ULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) Additional Inclusion Criteria Patients : Subject medically diagnose systemic amyloidosis Additional Inclusion Criteria Patients : serum amyloid P component ( SAP ) scan identify amyloid anatomical site , include subset patient moderatelarge amyloid load liver Additional Inclusion Criteria Patients : Up include New York Heart Association ( NYHA ) class 2 stable clinical cardiac status 12 week prior screen Additional Inclusion Criteria Patients : For Amyloid Lightchain ( AL ) amyloidosis patient , &gt; =12 month postchemotherapy stable free light chain ( FLC ) ratio precede 4 month Additional Inclusion Criteria Patients : estimate glomerular filtration rate ( eGFR ) &gt; 50 mL/minute Additional Inclusion Criteria Patients : Alanine amino transferase ( ALT ) &lt; =3x upper limit normal ( ULN ) bilirubin &lt; =1.5x ULN ( isolated bilirubin &gt; 1.5 xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) , irrespective alkaline phosphatase ( ALP ) level Additional Inclusion Criteria Patients : Subject ambulant capable attend clinical unit Prohibited medication History regular alcohol consumption within 6 month study define : For United Kingdom ( UK ) sit healthy volunteer : average weekly intake &gt; 21 unit male &gt; 14 unit female . One unit equivalent 8 gram ( g ) alcohol : halfpint ( approximately 240 mL ) beer , 1 glass ( 125 mL ) wine 1 ( 25 mL ) measure spirit . History sensitivity study medication , metabolite thereof history drug allergy , opinion investigator Medical Monitor , contraindicate participation Presence hepatitis B surface antigen ( HBsAg ) , positive hepatitis C antibody test result screen within 3 month prior first dose study treatment . A positive prestudy drug/alcohol screen A positive test human immunodeficiency virus ( HIV ) antibody Where participation study would result donation blood blood product excess 500 mL within 84 day The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Prior Part A subject participate Parts A B Exposure four new chemical entity within 12 month prior first dose day Lactating females Poor unsuitable venous access Additional Exclusion Criteria Healthy Volunteer : Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) Additional Exclusion Criteria Healthy Volunteer : correct QT interval use Fridericia 's formula ( QTcF ) &gt; 450 millisecond ( msec ) mean triplicate reading triplicate reading take 5 minute apart Additional Exclusion Criteria Patients : Subject mean QTcF &gt; 480 msec mean triplicate reading Additional Exclusion Criteria Patients : First degree heart block deem require pacing ; Second degree atrioventricular ( AV ) block Mobitz Type II ; Trifasicular block ; Ventricular tachyarrthymias exception bundle branch block , atrial fibrillation &amp; first degree heart block require pacing , second degree AV block Mobitz Type I Additional Exclusion Criteria Patients : 24 hour proteinuria &gt; =5 g Additional Exclusion Criteria Patients : A syncopal episode , causation , within 4 week screen Additional Exclusion Criteria Patients : Average systolic blood pressure ( SBP ) &lt; =90 millimeter mercury ( mmHg ) Screening triplicate reading Additional Exclusion Criteria Patients : Implantable cardiac defibrillator ( ICD ) Additional Exclusion Criteria Patients : Evidence severe cardiac dysfunction within 12 month screen , diagnosed cardiologist , use Echocardiography cardiac magnetic resonance imaging ( MRI ) i.e . markedly impaired ejection fraction ( EF ) ( EF &lt; 50 % cardiac amyloidosis patient ) , cardiac imaging parameter severe diastolic dysfunction ( grade 3 4 ) Additional Exclusion Criteria Patients : Anaemia hemoglobin &lt; 9 g/deciliter ( dL ) Additional Exclusion Criteria Patients : Uncontrolled hypertension know hypertensive patient , fulfil diagnostic criterion essential hypertension screen Additional Exclusion Criteria Patients : Presence comorbid condition ( e.g . severe unstable coronary artery disease ; moderate severe chronic obstructive pulmonary disease ) opinion investigator would increase potential risk subject Additional Exclusion Criteria Patients : Nonamyloidosis cause chronic liver disease ( exception Gilbert 's syndrome clinically asymptomatic gallstone ) Additional Exclusion Criteria Patients : Diabetes Mellitus Additional Exclusion Criteria Patients : Glycosuria Screening Additional Exclusion Criteria Patients : Urine power Hydrogen ( pH ) &lt; 6.0 screen Additional Exclusion Criteria Patients : Hypoalbuminemia ( &lt; 30 nanomoles [ nmol ] /L ) Additional Exclusion Criteria Patients : Hypophosphatemia ( less 0.8 millimoles [ mmol ] /L ) Additional Exclusion Criteria Patients : Prothombin time &gt; 1.5xULN Additional Exclusion Criteria Patients : Malabsorption syndrome aetiology Additional Exclusion Criteria Patients : Compassionate use CPHPC ( GSK2315698 ) participation separate clinical trial involve CPHPC within 3 month screen Additional Exclusion Criteria Patients : Currently take follow esterasecleaved prodrug medication : cerebyx , aquavan , spectracef , hepsera , viread Additional Exclusion Criteria Patients : Anticoagulation therapy within 4 week Screening Additional Exclusion Criteria Patients : Currently receive receive within 12 week screen immunosuppressive anticytokine monoclonal antibody ( e.g . antitumor necrosis factor [ antiTNF ] antiinterleukin 1 [ antiIL1 ] ) , disease modify drug ( e.g . methotrexate , gold cyclophosphamide ) , highdose infusional steroid ( e.g . methylprednisolone ) , exception lowdose maintenance oral corticosteroid ( e.g . &lt; =30 milligram ( mg ) prednisolone per day )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>GSK3039294</keyword>
	<keyword>GSK2315698</keyword>
	<keyword>systemic amyloidosis</keyword>
	<keyword>CPHPC</keyword>
	<keyword>dose-escalation</keyword>
</DOC>